Drug Discovery Global Market Report 2026

Drug discovery is the process of identifying biologically active compounds with the potential to become therapeutic agents. This process spans multiple phases, from ideation and development to regulatory approval. It is aimed at discovering new clinical drugs for the treatment of new, existing, and previously untreatable diseases.

The main types of drugs in the drug discovery market are small molecules and large molecules. Small molecules are low molecular weight drugs that can easily penetrate cells and are identified for their suitable properties for further development. The drug discovery process involves various stages, including target selection, target validation, hit-to-lead identification, lead optimization, and candidate validation. Key technologies used in drug discovery include high-throughput screening, spectroscopy, combinatorial chemistry, biochips, pharmacogenomics and pharmacogenetics, bioinformatics, metabolomics, nanotechnology, and others. Drug discovery finds applications across multiple therapeutic areas such as oncology, neurology, infectious and immune system diseases, digestive system diseases, cardiovascular diseases, diabetes, respiratory diseases, and more. It is utilized by pharmaceutical companies, contract research organizations (CROs), and other end-users.

Tariffs have impacted the drug discovery market by increasing the cost of imported laboratory equipment, high-throughput screening tools, and biotechnology reagents, causing supply chain disruptions across pharmaceutical and biotech companies. The small molecule and large molecule drug discovery segments, particularly in North America and Europe, are most affected due to reliance on imported technologies. However, tariffs have encouraged local manufacturing of certain reagents and instruments, fostering innovation and cost optimization in domestic markets. Overall, while costs may rise short-term, regional self-reliance could drive long-term efficiency.

The drug discovery market research report is one of a series of new reports from The Business Research Company that provides drug discovery market statistics, including drug discovery industry global market size, regional shares, competitors with a drug discovery market share, detailed drug discovery market segments, market trends and opportunities, and any further data you may need to thrive in the drug discovery industry. This drug discovery market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The drug discovery market size has grown rapidly in recent years. It will grow from $124.11 billion in 2025 to $142.54 billion in 2026 at a compound annual growth rate (CAGR) of 14.8%. The growth in the historic period can be attributed to rise in chronic and infectious diseases, advancements in molecular biology techniques, increase in r&d spending by pharmaceutical companies, growth in biotechnology collaborations, availability of research funding.

The drug discovery market size is expected to see rapid growth in the next few years. It will grow to $250.51 billion in 2030 at a compound annual growth rate (CAGR) of 15.1%. The growth in the forecast period can be attributed to emergence of ai-driven drug discovery platforms, expansion of personalized medicine, integration of omics data in drug design, growth in biopharmaceutical outsourcing, adoption of automation and robotics in laboratories. Major trends in the forecast period include high-throughput screening advancements, targeted drug development, personalized medicine approaches, integration of pharmacogenomics, nanotechnology-enabled drug discovery.

Rising healthcare expenditure is expected to drive growth in the drug discovery market over the coming years. Globally, countries are allocating a significant portion of their GDP to healthcare, including hospital care, physician and clinical services, dental services, residential and personal care, home healthcare, nursing facilities, continuing care retirement communities, prescription drugs, and more. Drug discovery represents a major component of this spending, as it is essential for developing treatments for diseases and extending life expectancy. The growing need for new drugs to address emerging diseases further fuels this trend. For example, in October 2024, the Centers for Medicare and Medicaid Services, a US-based federal agency, reported that national health expenditure grew 4.1% to $4.5 trillion in 2022, or $13,493 per person. Over 2023-2032, average national health expenditure growth (5.6%) is projected to outpace GDP growth (4.3%), raising healthcare spending as a share of GDP from 17.3% in 2022 to 19.7% in 2032. Therefore, increasing healthcare expenditures are supporting the expansion of the drug discovery market.

Key players in the drug discovery market are adopting new technologies, such as artificial intelligence (AI) and imaging technology, to shorten the time required for drug development. Imaging technology allows non-invasive visualization, characterization, and quantification of biological activities in organisms in response to drugs. These techniques, utilizing either probes or tissue properties, are critical for understanding diseases and developing new treatments. For instance, in May 2023, Google Cloud launched two AI-powered tools, the Target and Lead Identification Suite and the Multiomics Suite, to accelerate drug discovery and precision medicine. The Target and Lead Identification Suite aids in understanding the function of amino acids and proteins, while the Multiomics Suite speeds up the discovery and analysis of genomic data, facilitating the design of precision therapies.

In July 2024, Iktos, a France-based pharmaceutical and biotech company, acquired Synsight for an undisclosed amount. The acquisition aims to strengthen Iktos's platform by integrating Synsight's advanced technologies, particularly the MT Bench(TM) system for high-performance screening of biological interactions. Synsight is a France-based biotechnology company.

Major companies operating in the drug discovery market are Pfizer Inc., Merck & Co. Inc., Novartis International AG, Thermo Fisher Scientific Inc., WuXi AppTec Group, GlaxoSmithKline plc, Eli Lilly and Company, Laboratory Corporation of America Holdings, Evotec SE, Eurofins Scientific SE, Agilent Technologies Inc., Sanofi S.A., Charles River Laboratories International Inc., Pharmaron Ltd., Viva Biotech Ltd., Albany Molecular Research Inc., Schrodinger Inc., BioDuro Ltd., Aptuit LLC, Selvita S.A., Sygnature Discovery Limited, Jubilant Biosys Limited, Gero Limited, Domainex Ltd., Verge Genomics lnc., Aqemia SAS, BenevolentAI Limited, EPIVAX INC., ProteinQure lnc., Synlogic Inc., ChemPartner Co. Ltd., WuXi Biologics lnc., Abzena plc, Lonza Group Ltd., Catalent lnc., Recursion Pharmaceuticals Inc.

North America was the largest region in the drug discovery market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the drug discovery market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the drug discovery market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The drug discovery market includes revenues earned by entities by high throughput screening, spectroscopy, combinatorial chemistry, biochips, pharmacogenomics and pharmacogenetics, bioinformatics, metabolomics, and nanotechnology. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Drug Discovery Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses drug discovery market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for drug discovery ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The drug discovery market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Drug Type: Small Molecule; Large Molecule
• 2) By Process: Target Selection; Target Validation; Hit-To-Lead Identification; Lead Optimization; Candidate Validation
• 3) By Technology: High Throughput Screening; Spectroscopy; Combinatorial Chemistry; Biochips; Pharmacogenomics And Pharmacogenetics; Bioinformatics; Metabolomics; Nanotechnology; Other Technologies
• 4) By Therapeutic Area: Oncology; Neurology; Infectious And Immune System Diseases; Digestive System Diseases; Cardiovascular Diseases; Diabetes; Respiratory Disease; Other Therapeutic Areas
• 5) By End User: Pharmaceutical Companies; CROs; Other End-Users
• Subsegments:
• 1) By Small Molecule: Synthetic Small Molecules; Natural Small Molecules; Targeted Small Molecule Drugs
• 2) By Large Molecule: Monoclonal Antibodies; Proteins And Peptides; Nucleic Acid-Based Therapies
• Companies Mentioned: Pfizer Inc.; Merck & Co. Inc.; Novartis International AG; Thermo Fisher Scientific Inc.; WuXi AppTec Group; GlaxoSmithKline plc; Eli Lilly and Company; Laboratory Corporation of America Holdings; Evotec SE; Eurofins Scientific SE; Agilent Technologies Inc.; Sanofi S.A.; Charles River Laboratories International Inc.; Pharmaron Ltd.; Viva Biotech Ltd.; Albany Molecular Research Inc.; Schrodinger Inc.; BioDuro Ltd.; Aptuit LLC; Selvita S.A.; Sygnature Discovery Limited; Jubilant Biosys Limited; Gero Limited; Domainex Ltd.; Verge Genomics lnc.; Aqemia SAS; BenevolentAI Limited; EPIVAX INC.; ProteinQure lnc.; Synlogic Inc.; ChemPartner Co. Ltd.; WuXi Biologics lnc.; Abzena plc; Lonza Group Ltd.; Catalent lnc.; Recursion Pharmaceuticals Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.